ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Assessment of Rapid Optimized Flow Cytometric Crossmatch (FCXM) Assay with Luminex Class I Single Antibody Test

J. Yoo1, S. Lee2, J. Jang3, A. Choi2, E. Oh1

1Department of Laboratory Medicine, Catholic University of Korea, Seoul, Korea, Republic of, 2Department of Laboratory Medicine, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, 3Department of Biomedical Science, Graduate School, Catholic University of Korea, Seoul, Korea, Republic of

Meeting: 2020 American Transplant Congress

Abstract number: A-293

Keywords: Flowcytometry crossmatching, HLA antibodies

Session Information

Session Name: Poster Session A: Histocompatibility and Immunogenetics

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Flow cytometric crossmatch test (FCXM) is critical to detect donor-specific antibodies (DSA) in transplant patients. Rapid, simple and sensitive FCXM procedure can improve HLA compatibility judgments and diagnosis of antibody mediated rejection. The aim of this study was to assess the optimized Halifax protocol in association with the results of virtual crossmatch (VXM) based on the class I single antigen bead (SAB) assay.

*Methods: Halifax FCXM protocol includes a 96-well tray platform, reduced wash times, increased serum to cell suspension volume ratio, shortened incubations, and higher incubation temperature. The cut-off value was determined as the median fluorescence intensity (MFI) ratio with 3 standard deviations using forty-five PRA-negative sera. Among 316 T-XMs performed, 102 cases were class I- VXM positive. Of 102 VXM (+) cases, 55 cases showed only one class I HLA antigen-positive for serum, and 47 cases showed at least two antigens-positive for serum. Normalized MFI values above 1,000 were defined as a positive-VXM.

*Results: Of 55 cases with class I VXM positive against one HLA antigen (26 HLA-A, 25 HLA-B, 4 HLA-Cw), 39 (70.9%) cases were T-FCXM positive (21 (80.8%) HLA-A and 18 (72.0%) HLA-B). T-FCXM positive cases had higher MFI values than T-FCXM negative cases (P <0.05). Class I-VXM (+)/T-FCXM (-) cases had class I MFI values ranged 1037-3440 (Table1). Overall T-FCXM using Halifax protocol revealed excellent correlation with VXM (81.4% and 98.1% sensitivity and specificity, respectively) for the identification of DSA (HLA-A/B/Cw) above 1000 MFI values.

*Conclusions: The Halifax FCXM protocol showed comparable performance to VXM based on SAB results. The application of rapid and simple new protocol in clinical laboratories can be effective in detecting sensitized patients with a shorter assay time.

Table 1. T-FCXM results and MFI values of DSA against one heterozygous HLA antigen
DSA T-FCXM Number Median MFI Range
All loci (+) 39 2,760 1,037-15,533
(-) 16 1,308 1,036-3,440
HLA-A (+) 21 4,574 1,037-11,797
(-) 5 1,176 1,036-3440
HLA-B (+) 18 2,760 1,071-15,533
(-) 7 1,491 1,068-2,033
HLA-Cw (-) 4 1,140 1098-1643
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Yoo J, Lee S, Jang J, Choi A, Oh E. Assessment of Rapid Optimized Flow Cytometric Crossmatch (FCXM) Assay with Luminex Class I Single Antibody Test [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/assessment-of-rapid-optimized-flow-cytometric-crossmatch-fcxm-assay-with-luminex-class-i-single-antibody-test/. Accessed May 24, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences